|
gptkbp:instanceOf
|
gptkb:drug
tumor necrosis factor inhibitor
|
|
gptkbp:administeredBy
|
gptkb:physician
self-injection
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:ATCCode
|
gptkb:L04AB01
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:blackBoxWarning
|
malignancy
serious infections
|
|
gptkbp:brand
|
gptkb:Enbrel
|
|
gptkbp:CASNumber
|
gptkb:185243-69-0
|
|
gptkbp:contraindication
|
sepsis
|
|
gptkbp:cost
|
high
|
|
gptkbp:developer
|
gptkb:Pfizer
gptkb:Immunex
|
|
gptkbp:eliminatedIn
|
renal
hepatic
|
|
gptkbp:form
|
pre-filled syringe
auto-injector
|
|
gptkbp:halfLife
|
3-5 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Etanercept
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to tumor necrosis factor alpha
inhibits inflammatory response
|
|
gptkbp:metabolism
|
proteolytic enzymes
|
|
gptkbp:molecularWeight
|
150 kDa
|
|
gptkbp:monitoredParameter
|
gptkb:CBC
liver function tests
signs of infection
tuberculosis screening
|
|
gptkbp:patentExpired
|
2012 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescriptionRequired
|
FDA label
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
headache
injection site reaction
increased risk of infection
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target
|
gptkb:tumor_necrosis_factor_beta
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:UNII
|
3NXW29V3WO
|
|
gptkbp:usedFor
|
gptkb:juvenile_idiopathic_arthritis
gptkb:psoriatic_arthritis
rheumatoid arthritis
ankylosing spondylitis
plaque psoriasis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Biocon_Biologics
|
|
gptkbp:bfsLayer
|
7
|